Anzeige
Mehr »
Montag, 10.08.2026 - Börsentäglich über 12.000 News
Breaking News: Wirklich beeindruckende Ergebnisse
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41EEL | ISIN: US82537J1088 | Ticker-Symbol: VB3
Frankfurt
10.08.26 | 08:15
17,600 Euro
-8,33 % -1,600
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
SHOULDER INNOVATIONS INC Chart 1 Jahr
5-Tage-Chart
SHOULDER INNOVATIONS INC 5-Tage-Chart
PR Newswire
52 Leser
Artikel bewerten:
(0)

Shoulder Innovations Promotes Jon Osborne to Chief Commercial Officer

GRAND RAPIDS, Mich., Aug. 10, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the promotion of Jon Osborne to Chief Commercial Officer, effective August 6, 2026. Mr. Osborne, who most recently served as Vice President of Commercial Development, will now have responsibility for all elements of Shoulder Innovations' commercial organization and will work closely with its Customer Experience and Medical Education team to execute the company's commercial strategy.

"Jon has consistently demonstrated exceptional leadership since joining Shoulder Innovations, and this promotion reflects the impact he's had on our rapid commercial success as a key architect of our go-to-market strategy," said Rob Ball, CEO of Shoulder Innovations. "His depth of experience across the orthopedic industry, paired with his keen understanding of our business, strong relationships with our surgeon customers, and proven ability to execute, positions him well to lead our commercial organization as we continue to scale adoption of our broad and increasingly differentiated product portfolio."

"We're at an exciting point in our early journey of transforming the shoulder surgical care market for our customers and their patients, and I'm looking forward to building on the strong commercial foundation that the entire Shoulder Innovations team has worked hard to build," said Jon Osborne. "With this expanded role, my focus will be on further scaling the organization, deepening our surgeon and partner relationships, and ensuring our commercial execution keeps pace with the strength of our innovation engine."

Prior to joining Shoulder Innovations as Vice President of Commercial Development in September 2023, Mr. Osborne held several positions of increasing responsibility from 2014 to 2023 at Smith & Nephew Inc., most recently as Vice President of Commercial Marketing for the Sports Medicine business in the Americas. In this role, he was responsible for driving growth across a portfolio spanning joint repair, arthroscopic enabling technologies, biologics, and capital equipment, with additional oversight for outpatient and ambulatory surgery center initiatives. Earlier in his career at Smith & Nephew Inc., he also served as an Area Vice President of Sales and as Director of Global Marketing, where he launched products and built distribution across six continents.

Prior to Smith & Nephew, Mr. Osborne worked in sales management, global marketing, and general management from 1998 to 2014 in both domestic and international markets at ArthroCare Corporation, Tornier USA, and Team Surgical, Inc. Mr. Osborne received his Bachelor of Arts in Public Relations from Miami University in Oxford, Ohio, and his Master of Business Administration from the Leeds School of Business at the University of Colorado.

About Shoulder Innovations
Shoulder Innovations is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, with a current offering of advanced implant systems for shoulder arthroplasty. These systems are a core element of Shoulder Innovations' ecosystem, which is designed to improve core components of shoulder surgical care - preoperative planning, implant design and procedural efficiency - to benefit each stakeholder in the care chain. Shoulder Innovations' ecosystem is also comprised of enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration. Together, these elements seek to address the long-standing clinical and operational challenges in the shoulder surgical care market by delivering predictable outcomes, procedural simplicity, and efficiency across all sites of care.

Contact
Brian Johnston or Sam Bentzinger
Gilmartin Group LLC
[email protected]

SOURCE Shoulder Innovations

© 2026 PR Newswire
Achtung, Korrektur!
Die Börsen laufen heiß. Trotz geopolitischer Krisen und steigender Zinsen klettern viele Indizes weiter Richtung Allzeithoch. Doch unter der Oberfläche zeigen sich erste Risse: Der Abverkauf bei Halbleiter-, KI- und Space-Aktien macht deutlich, wie schnell sich die Stimmung drehen kann.

Besonders gefährlich ist die aktuelle Gemengelage aus schwacher Saisonalität, dünner Liquidität in den Sommermonaten und historisch hohen Bewertungen. Selbst vermeintlich sichere Blue Chips sind inzwischen teuer bewertet und damit anfällig für Korrekturen. Gleichzeitig liefern technische Indikatoren erste Warnsignale. So werden viele Rekordstände nicht mehr bestätigt.

Für Anleger steigen die Risiken spürbar. Wer jetzt nicht genauer hinschaut, läuft Gefahr, auf dem falschen Fuß erwischt zu werden.

In unserem aktuellen Spezialreport zeigen wir fünf Aktien, bei denen die Abwärtsrisiken besonders hoch sind – und wo sich Gewinnmitnahmen oder sogar Short-Strategien anbieten könnten.

Jetzt den kostenlosen Report sichern – bevor die Korrektur Fahrt aufnimmt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.